Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Key Inclusion Criteria:

1. Male or female aged 18 to 65 years at the time of consent.

2. Onset of migraine headache before age 50.

3. History of episodic migraine headache starting at least 1-year ago with or withoutaura.

4. Has a minimum of 4 monthly migraine days and not more than 10 migraine days permonth.

5. Able to distinguish pain related to migraine attacks from tension-type and clusterheadache attacks.

6. Able to understand and provide signed informed consent.

7. Willing and able to comply with all scheduled visits, treatment plan, and otherstudy procedures.

Key Exclusion Criteria:

1. No more than a total of 15 headache days per month.

2. Use of more than 2 migraine preventive medications.

3. Current diagnosis of glaucoma.

4. Use of opioids or barbiturates more than 4 days/month, triptans or ergots 10 or moredays/month, or simple analgesics (e.g., aspirin, NSAIDs, acetaminophen) 15 or moredays/month in the 3 months prior to Visit 1.

5. Current diagnosis of any post-traumatic headaches, medication overuse headaches, newdaily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache),painful cranial neuropathy or daily headaches.

6. Vaccination within less than 7 days from the Screening or plans to get a vaccineduring the study or within a week after final study dose.